Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
5.98
+0.01 (0.08%)
Apr 23, 2025, 4:00 PM EDT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
$228,102
Profits / Employee
-$2,291
Market Cap
10.93B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Northwest Biotherapeutics | 25 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Longduoduo Company | 49 |
Innovent Biologics News
- 19 hours ago - Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting - PRNewsWire
- 24 days ago - Innovent Biologics Inc (IVBIY) Secures Breakthrough Therapy Designation for IBI363 in Melanoma ... - GuruFocus
- 24 days ago - Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma - PRNewsWire
- 4 weeks ago - Innovent Biologics reports FY results - Seeking Alpha
- 4 weeks ago - Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting - PRNewsWire
- 4 weeks ago - Innovent Announces 2024 Annual Results and Business Updates - PRNewsWire
- 4 weeks ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer - PRNewsWire
- 5 weeks ago - Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - PRNewsWire